Designing and Development of imidazol-5-ones as NNRTIs

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) of HIV-1 are an important part of currently available anti-HIV therapies because of their diversity and specificity in targeting this enzyme. The use of NNRTIs in the clinic still remains subject to the rapid emergence of drug resistance due to mutation of the HIV-RT enzyme and this limits therapeutic options. So there is need to discover new chemical entity having broad spectrum activity against reverse transcriptase enzyme.

Autorentext

Dr. Santosh N. Mokale, M.Pharm Ph.D. is working as Professor at Y. B. Chavan College of Pharmacy, Aurangabad (MS). He has around 17 years of professional experience and has published 30 research papers with cumulative impact factor more than 50. He is recipient of YOUNG SCIENTIST award from DST and research grants Rs. 45 Lack from DST and UGC